CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma

Clin J Oncol Nurs. 2022 Nov 18;26(6):597-601. doi: 10.1188/22.CJON.597-601.

Abstract

Cellular immunotherapy with CD19-directed chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape for aggressive B-cell non-Hodgkin lymphoma (B-NHL). Three CAR T-cell therapies are commercially avai.

Keywords: B-cell lymphoma; CAR T-cell therapy; ICANS; cytokine release syndrome.

MeSH terms

  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Receptors, Antigen, T-Cell / therapeutic use
  • Receptors, Chimeric Antigen* / therapeutic use
  • T-Lymphocytes

Substances

  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell